Onapristone: Ph II halted

Arno said it halted enrollment in the Phase II portion of an open-label, U.K. Phase I/II trial evaluating twice-daily onapristone plus Zytiga abiraterone acetate after the company determined further enrollment was not justified based on data from the first 12 patients. The Phase II portion has enrolled 15 patients who have failed Zytiga alone. Last year, Arno discontinued a Phase I/II trial of onapristone in patients with endometrial cancer to focus on clinical development of the compound for metastatic CRPC (see BioCentury, April 25, 2016). The company said its board is evaluating all development, strategic or corporate opportunities available for onapristone, AR-42 and AR-12...